Cross-topic event
Sports/Healthdesk view
Phase 3 RCT: recombinant zoster vaccine LZ901 ~91.6% efficacy over ~12 months; ~66.9% in adults ≥70 (Public health)
Nature Communications (Aug 7, 2026) reported a multicenter, randomized, double-blind, placebo-controlled phase 3 trial (ChiCTR2300076253) in ~26,018 adults ≥40 …
READ THE DAY'S DIGEST →
Sciencedesk view
Luzhu’s LZ901 Shingles Vaccine Phase III Results Published in Nature Communications (Vaccines)
Beijing Luzhu Biotechnology reported that Phase III results for recombinant herpes zoster vaccine LZ901 appeared in Nature Communications on August 7, with indu…